Abiopharma

🔍 Seehra Jasbir (Executive)

Company: Keros Therapeutics, Inc. (KROS)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 62,500 shares of Employee Stock Option (right to buy) at $63.61 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2034-02-22 | equity_swap_involved: 0 | shares_owned_after: 62,500.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: On February 23, 2024, the Reporting Person filed a Form 4 with the SEC reporting the grant of an option to purchase 125,000 shares of common stock, the vesting of which was subject to the achievement of specified performance criteria. On January 7, 2026, the Compensation Committee of the Issuer's Board of Directors certified that (i) certain performance condition with respect to the option to purchase 62,500 shares had been met, resulting in the immediate vesting of 31,250 shares and the vesting of 31,250 shares on December 31, 2026, subject to the continuous service of the Reporting Person through such date, and (ii) certain performance condition with respect to the option to purchase 62,500 shares had not been met, resulting in the forfeiture of such option for no consideration.